GPx Mimetic Program

Synvista’s GPx mimetic program is based on the rational design of oral and topical drugs that mimic the activity of glutathione peroxidase (GPx), the only enzyme in the human body that reduces oxidized lipids.

GPx is a well validated target for drug development. Animal models have shown that elevated activity protects animals from experiencing heart attacks and atherosclerosis and reduced levels put them at risk for those diseases or complications. In humans, research suggests the risk of cardiovascular disease varies inversely with levels of GPx activity (i.e., higher levels of oxidized lipids promote the creation of oxygen free radicals and reactive oxygen species (ROS), such as H2O2, which can promote inflammation).

A topical form of our GPx mimetic SYI-2074 is being developed for mild to moderate plaque psoriasis, an inflammatory disease highly correlated with a molecular signaling pathway that can be inhibited by SYI-2074.

SYI-2074 and Psoriasis

Psoriasis is an immune-mediated chronic inflammatory disease usually characterized by red lesions or silvery white scales on the skin, which usually occur on the scalp, knees, elbows, the abdomen (around the navel) and the genitals. In about a quarter of the cases, psoriasis can lead to psoriatic arthritis, another inflammatory disease affecting the joints.

While the exact cause of the disease is unknown, it is believed that both genetic and hormonal factors play a role. It is also known that the TNF-α pathway plays a role in the progression of the disease. Other companies have successfully developed drugs that also interfere with TNF-α signaling, but these similar drugs are given as injections and are indicated for more severe forms of the disease. Synvista expects to differentiate itself by developing a topical formulation of SYI-2074 for the treatment of mild-to-moderate psoriasis.